Skip to Main Content

Author Details

Stanley K Liu
Odette Cancer Centre, University of Toronto
1995
99
30
PMIDPaper TitleJournal TitlePublished Year
36713978<sup>18</sup>F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer.Clin Transl Radiat Oncol2023
37619656Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.Radiother Oncol2023
37546794Prostate Cancer Reshapes the Secreted and Extracellular Vesicle Urinary Proteomes.bioRxiv2023
37419394To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.Int J Radiat Oncol Biol Phys2023
37278613Ultrasound-stimulated microbubbles enhanced vascular disruption in fractionated radiotherapy-treated tumours via ASMase activation.Dis Model Mech2023
37439544Native Mass Spectrometry Quantitation of α2-3-Linked <i>N</i>-Acetylneuraminic Acid Content of Prostate-Specific Antigen: An Accurate Liquid Biopsy for Clinically Significant Prostate Cancer.Anal Chem2023
36754232Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.Radiother Oncol2023
34103388Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression.J Clin Pathol2022
36230835Development of a Clinically Applicable NanoString-Based Gene Expression Classifier for Muscle-Invasive Bladder Cancer Molecular Stratification.Cancers (Basel)2022
35151715Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?Radiother Oncol2022
35302473Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer.Can Urol Assoc J2022
35027623Upregulation of IFNÉ£-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma.Sci Rep2022
34637882Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost.Int J Radiat Oncol Biol Phys2022
32471889Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.J Clin Pathol2021
34487764Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials.Radiother Oncol2021
34453155Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.Nat Rev Urol2021
34324914Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.Radiother Oncol2021
34152685A proteomic investigation of isogenic radiation resistant prostate cancer cell lines.Proteomics Clin Appl2021
34126044Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.Lancet Oncol2021
34089752Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.Radiother Oncol2021
33398023Reciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer.Commun Biol2021
33359269Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial.Radiother Oncol2021
32918971Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost.Radiother Oncol2021
31161221Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome.J Natl Cancer Inst2020
31874245miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.Cancer Lett2020
31809979Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy.Radiother Oncol2020
31919144Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder.J Clin Pathol2020
33277574Saturation transfer properties of tumour xenografts derived from prostate cancer cell lines 22Rv1 and DU145.Sci Rep2020
33006882Necessity and Challenges of Sample Preconcentration in Analysis of Multiple MicroRNAs by Capillary Electrophoresis.Anal Chem2020
32861170Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.Pathol Res Pract2020
33022560Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?Pathol Res Pract2020
32420197Urinary biomarkers in prostate cancer: to the miRnome and beyond.Transl Androl Urol2020
32415137An Automated Segmentation Pipeline for Intratumoural Regions in Animal Xenografts Using Machine Learning and Saturation Transfer MRI.Sci Rep2020
32146259Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.Radiother Oncol2020
32293453microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation.Mol Cancer2020
30445172SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation.Int J Radiat Oncol Biol Phys2019
31322262MicroRNAâ¿¿198 suppresses prostate tumorigenesis by targeting MIB1.Oncol Rep2019
30987640RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer.J Transl Med2019
30777394Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.Urol Oncol2019
30735634Widespread and Functional RNA Circularization in Localized Prostate Cancer.Cell2019
30881943Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies.Res Rep Urol2019
30643250Molecular landmarks of tumor hypoxia across cancer types.Nat Genet2019
27526692Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study).J Cancer Educ2018
30050794Stereotactic ablative body radiotherapy in patients with prostate cancer.Transl Androl Urol2018
30075156Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.Hum Pathol2018
29992999Differentiation of Normal and Radioresistant Prostate Cancer Xenografts Using Magnetization Transfer-Prepared MRI.Sci Rep2018
30071295Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.Int J Radiat Oncol Biol Phys2018
30257853Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis.J Clin Pathol2018
29845714miRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation.Mol Oncol2018
29947424Basal-subtype bladder tumours show a 'hot' immunophenotype.Histopathology2018
  • 1 - 50 of 99

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 4
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 1
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 8
Sungyong You
Cedars-Sinai Medical Center
Career Start Year 2008
Number of shared co-authors 3
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 1
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Career Start Year 2005
Number of shared co-authors 19
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 7
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 7
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 25
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Joshua M Lang
19University of Wisconsin Carbone Cancer Center.
Career Start Year 2000
Number of shared co-authors 6
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 0
David T Miyamoto
Massachusetts General Hospital
Career Start Year 2000
Number of shared co-authors 5
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 19
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 2
Leena Latonen
Foundation for the Finnish Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 1
Francesca M Buffa
University of Oxford
Career Start Year 1998
Number of shared co-authors 7
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 11
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 4
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 9
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 4
Kevin Camphausen
National Cancer Institute
Career Start Year 1994
Number of shared co-authors 1
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1993
Number of shared co-authors 35
Theodore L DeWeese
Johns Hopkins University School of Medicine
Career Start Year 1991
Number of shared co-authors 4
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 12
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 0
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 8
Beatrice S Knudsen
University of Utah
Career Start Year 1986
Number of shared co-authors 8
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 28

Collaborators

Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Co-authored papers 36
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Co-authored papers 24
Michelle R Downes
University of Toronto
Co-authored papers 17
Paul C Boutros
University of California los angeles
Co-authored papers 13
Xiaoyong Huang
Medical College, Yan'an University
Co-authored papers 11
Christianne Hoey
Evaluative Clinical Sciences, Sunnybrook Research Institute
Co-authored papers 9
Emmanouil Fokas
Universityhospital Frankfurt
Co-authored papers 8
Ekaterina Olkhov-Mitsel
University of Toronto
Co-authored papers 8
Jessica Ray
Sunnybrook Research Institute, University of Toronto
Co-authored papers 8
Samira Taeb
Sunnybrook Research Institute
Co-authored papers 8
Aruz Mesci
Juravinski Cancer Centre
Co-authored papers 7
Sergey N Krylov
York University
Co-authored papers 7
Elina Korpela
University of Toronto.
Co-authored papers 7
Robert G Bristow
University of Toronto
Co-authored papers 7
Kristina Commisso
University Health Network
Co-authored papers 6
Jouhyun Jeon
Ontario Institute for Cancer Research
Co-authored papers 5
Sahar Jahangiri
Tehran University of Medical Sciences
Co-authored papers 5
Bharati Bapat
Mt Sinai Hospital
Co-authored papers 4
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 3
Fang Zhao
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 3
Vincent Huang
Ontario Institute for Cancer Research
Co-authored papers 3
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 3
Farhad Ghasemi
Western University
Co-authored papers 3
Jane Bayani
Ontario Institute for Cancer Research
Co-authored papers 3
Renu Jeyapala
Toronto Metropolitan University
Co-authored papers 3
Thomas Kislinger
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 3
Lydia Y Liu
University of Toronto
Co-authored papers 3
Jeff P Bruce
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Yu-Jia Shiah
Ontario Institute for Cancer Research
Co-authored papers 2
Seville Scarcello
Sunnybrook Research Institute
Co-authored papers 2
Release 1.2